ECB-ART-49943
Oncol Lett
2019 Feb 01;172:2020-2030. doi: 10.3892/ol.2018.9856.
Show Gene links
Show Anatomy links
Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives.
Cao Z
,
Gao Q
,
Fu M
,
Ni N
,
Pei Y
,
Ou WB
.
Abstract
Receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK) serves a crucial role in brain development. ALK is located on the short arm of chromosome 2 (2p23) and exchange of chromosomal segments with other genes, including nucleophosmin (NPM), echinoderm microtubule-associated protein-like 4 (EML4) and Trk-fused gene (TFG), readily occurs. Such chromosomal translocation results in the formation of chimeric X-ALK fusion oncoproteins, which possess potential oncogenic functions due to constitutive activation of ALK kinase. These proteins contribute to the pathogenesis of various hematological malignancies and solid tumors, including lymphoma, lung cancer, inflammatory myofibroblastic tumors (IMTs), Spitz tumors, renal carcinoma, thyroid cancer, digestive tract cancer, breast cancer, leukemia and ovarian carcinoma. Targeting of ALK fusion oncoproteins exclusively, or in combination with ALK kinase inhibitors including crizotinib, is the most common therapeutic strategy. As is often the case for small-molecule tyrosine kinase inhibitors (TKIs), drug resistance eventually develops via an adaptive secondary mutation in the ALK fusion oncogene, or through engagement of alternative signaling mechanisms. The updated mechanisms of a variety of ALK fusions in tumorigenesis, proliferation and metastasis, in addition to targeted therapies are discussed below.
PubMed ID: 30675269
PMC ID: PMC6341817
Article link: Oncol Lett
References [+] :
Aisner,
ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
2014, Pubmed
Aisner, ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. 2014, Pubmed
Amatu, Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. 2015, Pubmed
Basit, First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib. 2017, Pubmed
Baudin, New therapeutic approaches for metastatic thyroid carcinoma. 2007, Pubmed
Bedwell, Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas. 2011, Pubmed
Bilsland, Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. 2008, Pubmed
Bloomfield, Inherent variability of cancer-specific aneuploidy generates metastases. 2016, Pubmed
Bloomfield, Is cancer progression caused by gradual or simultaneous acquisitions of new chromosomes? 2018, Pubmed
Bonvini, Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. 2002, Pubmed
Bridge, Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. 2001, Pubmed
Bunting, End-joining, translocations and cancer. 2013, Pubmed
Busam, Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions. 2014, Pubmed
Camidge, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. 2012, Pubmed
Ceccon, Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. 2013, Pubmed
Cheng, CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. 2012, Pubmed
Cheson, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. 2014, Pubmed
Choi, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. 2010, Pubmed , Echinobase
Choi, A novel fusion of TPR and ALK in lung adenocarcinoma. 2014, Pubmed , Echinobase
Chou, A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. 2015, Pubmed
Chun, Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis. 2005, Pubmed
Coffin, Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. 1995, Pubmed
Coffin, Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. 2007, Pubmed
Cools, Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. 2002, Pubmed
Crystal, Patient-derived models of acquired resistance can identify effective drug combinations for cancer. 2014, Pubmed
Cui, Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer. 2017, Pubmed
Damm-Welk, Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK. 2015, Pubmed
Debelenko, Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. 2011, Pubmed
Delsol, A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. 1997, Pubmed
Di Paolo, New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK. 2015, Pubmed
Doebele, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. 2012, Pubmed
Ettinger, Non-small cell lung cancer. 2012, Pubmed
Fang, HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. 2014, Pubmed
Feldman, Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. 2013, Pubmed
Gadgeel, Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. 2014, Pubmed
Gascoyne, ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. 2003, Pubmed
George, The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. 2014, Pubmed
Godbert, Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma. 2015, Pubmed
Griffin, Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. 1999, Pubmed
Guo, Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset. 2014, Pubmed
Gustafson, Anaplastic large cell lymphoma: another entity in the differential diagnosis of small round blue cell tumors. 2009, Pubmed
Heng, Why it is crucial to analyze non clonal chromosome aberrations or NCCAs? 2016, Pubmed
Hernández, TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. 1999, Pubmed
Heuckmann, ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. 2011, Pubmed
Hofman, Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. 2012, Pubmed
Holla, ALK: a tyrosine kinase target for cancer therapy. 2017, Pubmed
Horne, Evolutionary mechanism unifies the hallmarks of cancer. 2015, Pubmed
Huang, Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. 2016, Pubmed
Iyevleva, Novel ALK fusion partners in lung cancer. 2015, Pubmed
Jazii, Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. 2006, Pubmed
Ji, Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. 2014, Pubmed
Ji, Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. 2015, Pubmed , Echinobase
Johnson, Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. 2014, Pubmed
Katayama, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. 2012, Pubmed
Katayama, Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. 2011, Pubmed , Echinobase
Katayama, Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. 2014, Pubmed
Kelly, Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. 2014, Pubmed
Kodama, Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. 2014, Pubmed
Koivunen, EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. 2008, Pubmed
Kusano, Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene. 2016, Pubmed
Kwak, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. 2010, Pubmed
Lamant, Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. 2003, Pubmed
Lamant, A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. 1999, Pubmed
Laurent, Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. 2009, Pubmed
Lawrence, TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. 2000, Pubmed
Lee, Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. 2012, Pubmed
Lee, Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. 2015, Pubmed
Leuschner, [Inflammatory myofibroblastic tumor]. 2010, Pubmed
Li, Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. 2014, Pubmed , Echinobase
Li, Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. 2013, Pubmed
Liang, Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. 2004, Pubmed
Lin, Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. 2009, Pubmed , Echinobase
Lovly, Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. 2011, Pubmed
Lovly, Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. 2014, Pubmed
Ma, Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. 2003, Pubmed
Mariño-Enríquez, ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. 2013, Pubmed
Mariño-Enríquez, ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. 2011, Pubmed
Medeiros, Anaplastic Large Cell Lymphoma. 2007, Pubmed
Mengoli, K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature. 2016, Pubmed
Mologni, NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. 2015, Pubmed
Mori, The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. 2014, Pubmed , Echinobase
Morris, Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. 1994, Pubmed
Morris, Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. 1995, Pubmed
Ninomiya, Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes. 2013, Pubmed
Nishino, Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. 2012, Pubmed
Normant, The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. 2011, Pubmed , Echinobase
Onoda, Identification of novel ALK rearrangement A2M-ALK in a neonate with fetal lung interstitial tumor. 2014, Pubmed
Ou, Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. 2012, Pubmed
Ou, Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. 2014, Pubmed
Ouchi, FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor. 2015, Pubmed
Panagopoulos, Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. 2006, Pubmed
Pekar-Zlotin, Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. 2015, Pubmed
Popat, Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. 2011, Pubmed
Rassouli, Cancer stem cells in human digestive tract malignancies. 2016, Pubmed
Ren, Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. 2012, Pubmed
Rikova, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. 2007, Pubmed
Rodig, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. 2009, Pubmed
Roskoski, Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. 2013, Pubmed
Röttgers, ALK fusion genes in children with atypical myeloproliferative leukemia. 2010, Pubmed
Sakamoto, CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. 2011, Pubmed
Sang, Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. 2013, Pubmed
Sasaki, The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. 2010, Pubmed
Savage, ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. 2008, Pubmed
Seo, Clinicopathologic and Molecular Pathology of Collecting Duct Carcinoma and Related Renal Cell Carcinomas. 2017, Pubmed
Sequist, Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. 2010, Pubmed
Seto, CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. 2013, Pubmed
Shaozhang, Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations. 2012, Pubmed
Shaw, ALK in lung cancer: past, present, and future. 2013, Pubmed
Shaw, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. 2009, Pubmed
Shaw, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. 2013, Pubmed
Shaw, Ceritinib in ALK-rearranged non-small-cell lung cancer. 2014, Pubmed
Shaw, Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. 2016, Pubmed
Shimada, An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. 2017, Pubmed
Smallridge, Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. 2010, Pubmed
Soda, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 2007, Pubmed , Echinobase
Sokai, Pulmonary inflammatory myofibroblastic tumor harboring EML4-ALK fusion gene. 2014, Pubmed
Solomon, First-line crizotinib versus chemotherapy in ALK-positive lung cancer. 2014, Pubmed
Stöhr, [Histopathology of renal cell carcinoma]. 2013, Pubmed
Sukov, ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. 2012, Pubmed
Takeuchi, Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. 2011, Pubmed
Takeuchi, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. 2009, Pubmed
Takeuchi, Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. 2011, Pubmed
Togashi, KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. 2012, Pubmed
Torre, Global cancer statistics, 2012. 2015, Pubmed
Tort, Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. 2001, Pubmed
Trinei, A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. 2000, Pubmed
Van Roosbroeck, ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. 2010, Pubmed
Wang, Fusion of dynactin 1 to anaplastic lymphoma kinase in inflammatory myofibroblastic tumor. 2012, Pubmed
Wiesner, Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. 2014, Pubmed
Wong, The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. 2009, Pubmed , Echinobase
Xing, Molecular pathogenesis and mechanisms of thyroid cancer. 2013, Pubmed
Yao, Anaplastic lymphoma kinase is required for neurogenesis in the developing central nervous system of zebrafish. 2013, Pubmed
Ye, Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems. 2018, Pubmed
Yeh, Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. 2015, Pubmed
Ying, Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population. 2015, Pubmed
Zhang, Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. 2010, Pubmed
Zou, PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. 2015, Pubmed
d'Amore, STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target. 2013, Pubmed